Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_assertion type Assertion NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_head.
- NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_assertion description "[Ibrutinib (previously known as PCI-32765) has recently shown encouraging clinical activity in chronic lymphocytic leukaemia (CLL) effecting cell death through inhibition of Bruton's tyrosine kinase (BTK).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_provenance.
- NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_assertion evidence source_evidence_literature NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_provenance.
- NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_assertion SIO_000772 22975686 NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_provenance.
- NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_assertion wasDerivedFrom befree-2016 NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_provenance.
- NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_assertion wasGeneratedBy ECO_0000203 NP1012824.RAh0w4pWvFJgwpE13NxkCOocyO44hIe6sxjZ_N2qT_OX8130_provenance.